Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | PPARD | Q03181 | 4/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10636093 | 0.99 | CYP4F2 (0.52) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL7082197 | 0.94 | CYP4F2 (0.55) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL29587502 | 0.85 | CYP4F2 (0.53) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL10638633 | 0.84 | MAOB (0.49) | CYP4F2CYP4A11PPARGPPARACYSLTR1 | |
| SCHEMBL24496702 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL29586780 | 0.83 | PPARG (0.54) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL7313853 | 0.83 | CYP4F2 (0.60) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL7313848 | 0.83 | CYP4F2 (0.60) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL7313860 | 0.83 | CYP4F2 (0.60) | CYP4F2CYP4A11PPARGPPARAPPARD | |
| SCHEMBL6799118 | 0.83 | PPARG (0.54) | CYP4F2CYP4A11PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | CYP4F2 1369/4885CYP4A11 2064/4885PPARG 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.